184 related articles for article (PubMed ID: 32865474)
1. Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen.
Hagen P; D'Souza A; Hari P; Davila O; Zhang MJ; Vesole DH; Smith SE; Rodriguez TE; Stiff PJ
Leuk Lymphoma; 2020 Dec; 61(14):3484-3492. PubMed ID: 32865474
[TBL] [Abstract][Full Text] [Related]
2. Busulfan, melphalan and carfilzomib high-dose chemotherapy and autologous haematopoietic stem cell transplantation in multiple myeloma.
Hagen P; Norton J; Tsai S; Campo L; Lee M; Gomez K; Stiff P
Br J Haematol; 2024 Apr; 204(4):1422-1428. PubMed ID: 38176404
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of a new high-dose regimen of panobinostat, gemcitabine, busulfan, and melphalan for 1st or 2nd salvage ASCT for refractory/relapsed or high-risk myeloma: Matched-pair comparisons with concurrent control cohorts.
Nieto Y; Yang Z; Valdez BC; Kundu S; Bashir Q; Ramdial J; Srour S; Qazilbash M
Am J Hematol; 2024 Feb; 99(2):245-253. PubMed ID: 38100199
[TBL] [Abstract][Full Text] [Related]
4. In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT.
Beksac M; Eikema DJ; Koster L; Hulin C; Poiré X; Hamladji RM; Gromek T; Bazarbachi A; Ozkurt ZN; Pabst T; Ben Othman T; Finke J; Pirogova O; Wu D; Hayat A; Hilgendorf I; Tholouli E; de Wreede LC; Schönland S; Garderet L; Drozd-Sokolowska J; Raj K; Hayden PJ; Yakoub-Agha I; McLornan DP
Bone Marrow Transplant; 2024 Apr; 59(4):526-533. PubMed ID: 38297040
[TBL] [Abstract][Full Text] [Related]
5. Roussel M, Lauwers-Cances V, Macro M, et al. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study. Blood. 2022;139(18):2747-2757.
Blood; 2023 Mar; 141(10):1234. PubMed ID: 36893003
[No Abstract] [Full Text] [Related]
6. Clinical factors associated with autologous stem cell transplantation outcomes in multiple myeloma: upfront transplant with MEL200 remains the standard of care.
Bostankolu Değirmenci B; Yegin ZA; Akdemir ÜÖ; Dede A; Gündem GG; Özkurt ZN; Atay LÖ; Yağcı M
Ann Hematol; 2024 Jan; 103(1):269-283. PubMed ID: 37880484
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of busulfan-based conditioning regimens for multiple myeloma.
Reece D; Song K; LeBlanc R; Mezzi K; Olujohungbe A; White D; Zaman F; Belch A
Oncologist; 2013; 18(5):611-8. PubMed ID: 23628980
[TBL] [Abstract][Full Text] [Related]
8. Optimizing high dose melphalan.
Shah G; Giralt S; Dahi P
Blood Rev; 2024 Mar; 64():101162. PubMed ID: 38097487
[TBL] [Abstract][Full Text] [Related]
9. Survival outcomes following autologous stem cell transplant with melphalan 140mg/m
Sharma N; Benson E; Zhao Q; Nunnelee J; Cottini F; Elder P; Rosko A; Bumma N; Khan A; Umyarova E; Devarakonda S; Efebera YA; Benson DM
Leuk Lymphoma; 2023; 64(7):1315-1321. PubMed ID: 37199099
[TBL] [Abstract][Full Text] [Related]
10. Busulfan/Cyclophosphamide Compared with Melphalan as a Conditioning Regimen for Autologous Transplantation of Multiple Myeloma: A Long-Term Assessment.
Zhou S; Zhai Y; Yan L; Shi X; Shang J; Wu D; Fu C; Jin S
J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834886
[TBL] [Abstract][Full Text] [Related]
11. A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL).
Visram A; Hayman SR; Dispenzieri A; Kapoor P; Lacy MQ; Gertz MA; Buadi FK; Dingli D; Warsame R; Kourelis T; Cook J; Binder M; Gonsalves W; Muchtar E; Leung N; Roy V; Rajkumar SV; Kumar S
Am J Hematol; 2023 Aug; 98(8):1277-1285. PubMed ID: 37334773
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma.
Lee SR; Kim SJ; Park Y; Sung HJ; Choi CW; Kim BS
Korean J Hematol; 2010 Sep; 45(3):183-7. PubMed ID: 21120207
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Renal Impairment in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation With Melphalan Conditioning.
Ursu SG; Maples S; Williams KJ; Patrus G; Samhouri Y; Fazal S; Mewawalla P; Sadashiv S
J Hematol; 2023 Oct; 12(5):201-207. PubMed ID: 37936977
[TBL] [Abstract][Full Text] [Related]
14. Assessing Outcomes in Patients With Multiple Myeloma Postautologous Stem Cell Transplantation: Contrasting the Effects of Melphalan Dosages at 200 mg/m
Brown Z; Scott C; Zhang LF; Sadek R; Clarke A; Jillella A; Keruakous AR; Clemmons AB
Clin Lymphoma Myeloma Leuk; 2024 May; ():. PubMed ID: 38845275
[TBL] [Abstract][Full Text] [Related]
15. Impact of timing of stem cell return following high dose melphalan in multiple myeloma patients with renal impairment: a single center experience.
Nesr G; Shah R; Kyriakou C; Sive J; Popat R; Yong K; Wisniowski B; Xu K; Wechalekar A; Lee L; Ings S; Papanikolaou X; Mahmood S; Mcmillan A; Horder J; Newrick F; Marfil J; Ainley L; Asher S; Cheesman S; Rabin N
Leuk Lymphoma; 2023; 64(8):1465-1471. PubMed ID: 37259553
[TBL] [Abstract][Full Text] [Related]
16. Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis.
Ragon BK; Shah MV; D'Souza A; Estrada-Merly N; Gowda L; George G; de Lima M; Hashmi S; Kharfan-Dabaja MA; Majhail NS; Banerjee R; Saad A; Hildebrandt GC; Mian H; Abid MB; Battiwalla M; Lekakis LJ; Patel SS; Murthy HS; Nieto Y; Strouse C; Badawy SM; Al Hadidi S; Dholaria B; Aljurf M; Vesole DH; Lee CH; Pawarode A; Gergis U; Miller KC; Holmberg LA; Afrough A; Solh M; Munshi PN; Nishihori T; Anderson LD; Wirk B; Kaur G; Qazilbash MH; Shah N; Kumar SK; Usmani SZ
Blood Adv; 2023 Jun; 7(12):2746-2757. PubMed ID: 36827681
[TBL] [Abstract][Full Text] [Related]
17. Historical Perspective of High-Dose Therapy Followed by Autologous Stem Cell Transplantation in Multiple Myeloma.
Cohen I; Vaxman I; Gertz MA
Acta Haematol; 2024 May; ():1-10. PubMed ID: 38710160
[TBL] [Abstract][Full Text] [Related]
18. Microbiota dysbiosis after high-dose melphalan and autologous hematopoietic cell transplantation in multiple myeloma.
Malard F; Battipaglia G; Gaugler B; Siblany L; van de Wyngaert Z; Bonnin A; Duléry R; Banet A; Stocker N; Ricard L; Brissot E; Mohty M
Bone Marrow Transplant; 2023 Nov; 58(11):1275-1278. PubMed ID: 37608072
[No Abstract] [Full Text] [Related]
19. Safety and Efficacy of High-Dose Chemotherapy with TreoMel 200 vs. TreoMel 140 in Acute Myeloid Leukemia Patients Undergoing Autologous Stem Cell Transplantation.
Eggimann M; Akhoundova D; Nilius H; Hoffmann M; Hayoz M; Aebi Y; Largiadèr CR; Daskalakis M; Bacher U; Pabst T
Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38791965
[TBL] [Abstract][Full Text] [Related]
20. Investigating the effect of pre-transplant thrombocytopenia and anemia on the engraftment and long-term survival in multiple myeloma patients.
Kadkhoda D; Nikoonezhad M; Bonakchi H; Mehdizadeh M; Hajifathali A; Baghestani AR; Jabarinanva L; Khadem Maboudi AA
Transpl Immunol; 2024 Feb; 82():101991. PubMed ID: 38199269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
